Key facts
- Pacific Diabetes Technologies’s last known valuation is $30.7M (Mar 2025).
- It has raised $17.6M across 3 recorded rounds; the latest was Seed Round ($3.4M) in Oct 2025.
- Notable investors include National Institutes of Health, Breakthrough T1D, The Leona M. and Harry B. Helmsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases, Portland State University Business Accelerator — 6 tracked in total.
- Pacific Diabetes Technologies has filed 5 Form Ds with the SEC since 2021, most recently Nov 2025 ($3.4M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Pacific Diabetes Technologies
Funding rounds
3 roundsAbout Pacific Diabetes Technologies
Developer of hollow glucose sensor devices designed for continuous glucose monitoring and insulin delivery. The company's device aims to reduce the pain and daily disruption of managing insulin-treated diabetes and automated insulin delivery systems, enabling healthcare professionals to reduce needle trauma, and adhesive irritation, and improve adherence among pediatric and reluctant adult patient
- Sector
- Healthcare
- HQ
- Portland, OR, United States
- Founded
- 2013
- Employees
- 15
- Website
- pacificdt.com/
- Ownership
- Privately Held (backing)
Pacific Diabetes Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pacific Diabetes Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pacific Diabetes Technologies in its N-PORT filings yet. We sweep new filings monthly.